News Novo Nordisk may drop US insulin price as Sanofi suffers Biosimilar Lantus is causing rivals to cut prices to compete
News Ablynx and Sanofi sign potential 2.4bn euro R&D deal Collaboration will develop drugs for inflammatory diseases
News Amicus to file Fabry drug after FDA changes mind Regulator drops demand for further phase 3 trial.
News Sanofi $750m acquisition gives it edge in flu vacccine marke... Biotech's Flublok is only FDA-approved cell-based flu jab
News Sanofi's RA drug Kevzara approved in Europe Sanofi’s next-generation rheumatoid arthritis drug Kevzara has been approved in Europe, giving a new option for patients who are intolerant to other treatments.
News Court sides with EU on decision to revoke Ocaliva's license Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
